These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29392921)

  • 41. Altered expression of signalling lymphocyte activation molecule receptors in T-cells from lupus nephritis patients-a potential biomarker of disease activity.
    Stratigou V; Doyle AF; Carlucci F; Stephens L; Foschi V; Castelli M; McKenna N; Cook HT; Lightstone L; Cairns TD; Pickering MC; Botto M
    Rheumatology (Oxford); 2017 Jul; 56(7):1206-1216. PubMed ID: 28387859
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study.
    Mehra S; Usdadiya JB; Jain VK; Misra DP; Negi VS
    Rheumatol Int; 2018 Apr; 38(4):557-568. PubMed ID: 29450636
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CD3(+)CD8(+)CD28(-) T Lymphocytes in Patients with Lupus Nephritis.
    Żabińska M; Krajewska M; Kościelska-Kasprzak K; Klinger M
    J Immunol Res; 2016; 2016():1058165. PubMed ID: 27446964
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peripheral blood T-cell subset and its clinical significance in lupus nephritis patients.
    Wang H; Lan L; Chen J; Xiao L; Han F
    Lupus Sci Med; 2022 Aug; 9(1):. PubMed ID: 35973743
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exacerbation of lupus nephritis by high sodium chloride related to activation of SGK1 pathway.
    Yang X; Yao G; Chen W; Tang X; Feng X; Sun L
    Int Immunopharmacol; 2015 Dec; 29(2):568-573. PubMed ID: 26474695
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Indoleamine 2,3-dioxygenase-expressing peripheral cells in rheumatoid arthritis and systemic lupus erythematosus: a cross-sectional study.
    Furuzawa-Carballeda J; Lima G; Jakez-Ocampo J; Llorente L
    Eur J Clin Invest; 2011 Oct; 41(10):1037-46. PubMed ID: 21366559
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Imbalance of Th17/Treg cells ratio in peripheral blood of patients with immune thrombocytopenia].
    Cao J; Li XQ; Chen C; Zeng LY; Cheng H; Li ZY; Pang XY; Xu KL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Jun; 19(3):730-3. PubMed ID: 21729560
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Single-dose rituximab in refractory lupus nephritis.
    Kotagiri P; Martin A; Hughes P; Becker G; Nicholls K
    Intern Med J; 2016 Aug; 46(8):899-901. PubMed ID: 27242250
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Corticosteroids combined with doublet or single-agent immunosuppressive therapy for active proliferative lupus nephritis.
    Liu B; Ou Q; Tang Y; Fu S; Liang P; Yu Y; Xu Z; Chen Y; Xu A
    Clin Rheumatol; 2019 Sep; 38(9):2519-2528. PubMed ID: 31081535
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Peripheral Immunophenotyping Identifies Three Subgroups Based on T Cell Heterogeneity in Lupus Patients.
    Kubo S; Nakayamada S; Yoshikawa M; Miyazaki Y; Sakata K; Nakano K; Hanami K; Iwata S; Miyagawa I; Saito K; Tanaka Y
    Arthritis Rheumatol; 2017 Oct; 69(10):2029-2037. PubMed ID: 28605137
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice.
    Tanaka H; Watanabe S; Aizawa-Yashiro T; Oki E; Kumagai N; Tsuruga K; Ito E
    Nephron Clin Pract; 2012; 121(3-4):c165-73. PubMed ID: 23327881
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of different hepatitis B infection status on the prognosis of active lupus nephritis treated with immunosuppression: a retrospective analysis of 177 patients.
    Fang J; Li W; Tan M; Peng X; Tan Z; Wang W
    Int J Rheum Dis; 2018 May; 21(5):1060-1067. PubMed ID: 29878614
    [TBL] [Abstract][Full Text] [Related]  

  • 53. What happens after complete withdrawal of therapy in patients with lupus nephritis.
    Moroni G; Longhi S; Giglio E; Messa P; Ponticelli C
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S75-81. PubMed ID: 24129143
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Altered Th17 cells and Th17/regulatory T-cell ratios indicate the subsequent conversion from undifferentiated connective tissue disease to definitive systemic autoimmune disorders.
    Szodoray P; Nakken B; Barath S; Csipo I; Nagy G; El-Hage F; Osnes LT; Szegedi G; Bodolay E
    Hum Immunol; 2013 Dec; 74(12):1510-8. PubMed ID: 23974054
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognosis of proliferative lupus nephritis subsets in the Louvain Lupus Nephritis inception Cohort.
    Vandepapelière J; Aydin S; Cosyns JP; Depresseux G; Jadoul M; Houssiau FA
    Lupus; 2014 Feb; 23(2):159-65. PubMed ID: 24300780
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Urinary prostaglandin D synthase as biomarker in lupus nephritis: a longitudinal study.
    Gupta R; Yadav A; Misra R; Aggarwal A
    Clin Exp Rheumatol; 2015; 33(5):694-8. PubMed ID: 26211517
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mapping urinary chemokines in human lupus nephritis: Potentially redundant pathways recruit CD4
    Klocke J; Kopetschke K; Grießbach AS; Langhans V; Humrich JY; Biesen R; Dragun D; Radbruch A; Burmester GR; Riemekasten G; Enghard P
    Eur J Immunol; 2017 Jan; 47(1):180-192. PubMed ID: 27753073
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of regulatory T cells with renal outcomes in patients with proliferative lupus nephritis.
    Wang J; Zhu M; Jiao C; Xu X; Xu F; Liang D; Liu Z; Chen Y; Zhang H
    Lupus; 2023 Oct; 32(11):1237-1244. PubMed ID: 37695664
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers.
    Kopetschke K; Klocke J; Grießbach AS; Humrich JY; Biesen R; Dragun D; Burmester GR; Enghard P; Riemekasten G
    Arthritis Res Ther; 2015 Apr; 17(1):94. PubMed ID: 25890061
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting IL-6 signalling in early rheumatoid arthritis is followed by Th1 and Th17 suppression and Th2 expansion.
    Guggino G; Giardina AR; Raimondo S; Giardina G; Sireci G; Dieli F; Peralta M; Alessandro R; Triolo G; Ciccia F
    Clin Exp Rheumatol; 2014; 32(1):77-81. PubMed ID: 24429356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.